OrchidPharma
A Dhanuka Group Company

November 14, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Symbol: **ORCHPHARMA**

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai-400001

Scrip Code: **524372**

Subject: Outcome of Board Meeting – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30 read with Part A Para A of Schedule III and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026, SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 and in continuation to the prior intimation given by the Company on November 11, 2026 for scheduling the Board Meeting, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. November 14, 2026 (commenced at 12:00 Noon (IST) and concluded at 04:00 P.M. (IST) has, *inter-alia,* considered and approved the Unaudited limited reviewed Standalone & Consolidated Financial Results of the Company for quarter and half year ended on September 30, 2026 along with the auditors' limited review reports on standalone and consolidated quarterly financial results, issued by M/s. Singhi & Co., Statutory Auditors of the Company, enclosed herewith as **Annexure-I**.

You are requested to take the above intimations on record.

Thanking You,
For **Orchid Pharma Limited**

ORCHID PHARMA LIMITED Gurgaon

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No. F10698

Encl. as above

Annexure-I

Orchid Pharma Limited

Regd Office: Plot Nos. 121 – 128, 128A – 133, 138 – 151, 159 – 164, SIDCO Industrial Estate, Alathur, Chengalpattu District – 603110, Tamil Nadu, India
Ph. +91 - 44 - 2744 4471 - 78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com
CIN : L24222TN1992PLC022994

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026

(All amounts are in lakhs of Indian Rupees, unless otherwise stated)

S. No.	Particulars	Standalone financial results						Consolidated financial results					
		For the quarter ended			Six month ended		For the year ended	For the quarter ended			Six month ended		For the year ended
		Sep 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	Sep 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	March 31, 2026 Revised (Audited) (Refer Note 6)	Sep 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	Sep 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	March 31, 2026 Revised (Audited) (Refer Note 6)
	Income from Operations												
1	Net Sales / Income from operations	34,126.66	30,417.13	29,845.86	64,543.79	56,164.44	1,23,277.84	34126.66	30,417.13	29,845.86	64543.79	56,164.44	123277.84
2	Other Income	2,863.08	1,004.72	1,628.93	3,867.80	3,234.19	5,648.69	1775.58	182.84	1,163.85	1958.42	2,320.83	3641.83
3	**Total Income (1+2)**	**36,989.74**	**31,421.85**	**31,474.79**	**68,411.59**	**59,398.63**	**1,28,926.53**	**35,902.24**	**30,599.97**	**31,009.71**	**66,502.21**	**58,485.27**	**1,26,919.67**
4	**Expenses**												
	Cost of materials consumed	24,596.17	20,642.20	17,205.03	45,238.37	37,574.81	77,139.16	24596.17	20,642.20	17,205.03	45238.37	37,574.81	77139.16
	Changes in inventories of raw material, work-in-progress, stock-in-trade and finished goods	(3,895.02)	(272.47)	3,478.90	(4,167.49)	1,369.43	7,138.39	(3,895.02)	(272.47)	3,478.90	(4,167.49)	1,369.43	7138.39
	Purchases of Stock in trade	142.24	60.65	17.34	202.89	96.13	168.72	142.24	60.65	17.34	202.89	96.13	168.72
	Employee benefit expenses	3,268.50	2,675.81	3,063.70	5,944.31	5,833.50	11,432.05	3140.52	2,803.79	3,144.07	5944.31	5,913.87	11765.46
	Finance costs	366.12	221.23	256.81	587.35	485.29	896.15	364.33	223.02	256.81	587.35	485.29	898.43
	Depreciation and amortization expense	1,131.64	1,090.16	1,070.25	2,221.80	2,123.71	4,335.60	1141.19	1,094.91	1,081.26	2236.1	2,134.72	4324.63
	Other expenses	7,704.16	5,810.55	5,691.96	13,514.71	11,465.50	23,621.17	7729.12	5,782.92	5,692.10	13512.04	11,465.98	23708.71
	Total Expenses	**33,313.81**	**30,228.13**	**30,783.99**	**63,541.94**	**58,948.37**	**1,24,731.24**	**33,218.55**	**30,335.02**	**30,875.51**	**63,553.57**	**59,040.23**	**1,25,143.50**
5	**Profit / (Loss) before exceptional items and tax (3-4)**	**3,675.93**	**1,193.72**	**690.80**	**4,869.65**	**450.26**	**4,195.29**	**2,683.69**	**264.95**	**134.20**	**2,948.64**	**(554.96)**	**1,776.17**
6	Exceptional items (refer Note no.3)	-	-	-	-		(733.29)	-	-	-	-		(733.29)
7	**Profit / (Loss) before tax (5+6)**	**3,675.93**	**1,193.72**	**690.80**	**4,869.65**	**450.26**	**3,462.00**	**2,683.69**	**264.95**	**134.20**	**2,948.64**	**(554.96)**	**1,042.88**
8	**Tax expense**												
	Current tax	-	-	-	-		-	-		-			
	Tax adjustments of earliear years			-				-	-	-	-		-
	Deferred tax	-	-	-	-		-	(4.49)	7.23	(14.83)	2.74	(14.83)	(19.16)
	Total Tax Expenses	-	-	-	-		-	(4.49)	7.23	(14.83)	2.74	(14.83)	(19.16)
9	**Profit / (Loss) for the period before share of profit of Associates (7-8)**	**3,675.93**	**1,193.72**	**690.80**	**4,869.65**	**450.26**	**3,462.00**	**2,688.18**	**257.72**	**149.03**	**2,945.90**	**(540.13)**	**1,062.04**

SINGHI & CO. Chartered Accountants

ORCHID PHARMA LIMITED Gurgaon

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd...)

S. No.	Particulars	Standalone financial results						Consolidated financial results					
		For the quarter ended			Six month ended		For the year ended	For the quarter ended			Six month ended		For the year ended
		Sep 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	Sep 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	March 31, 2026 Revised (Audited) (Refer Note 6)	Sep 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	Sep 30, 2026 (Unaudited)	Sep 30, 2025 Revised (Unaudited) (Refer Note 6)	March 31, 2026 Revised (Audited) (Refer Note 6)
10	**Profit / (Loss) for the period before share of profit of Associates**	**3,675.93**	**1,193.72**	**690.80**	**4,869.65**	**450.26**	**3,462.00**	**2,688.18**	**257.72**	**149.03**	**2,945.90**	**(540.13)**	**1,062.04**
11	**Add: Share of Profit/ (Loss) of Associates**	-	-	-	-	-	-	171.23	64.72	(238.87)	235.95	(118.93)	(66.13)
12	**Profit / (Loss) for the period (10+11)**	**3,675.93**	**1,193.72**	**690.80**	**4,869.65**	**450.26**	**3,462.00**	**2,859.41**	**322.44**	**(89.84)**	**3,181.85**	**(659.06)**	**995.91**
13	**Other comprehensive income, net of income tax**												
	a) (i) items that will not be reclassified to profit or loss	(30.70)	0.64	(39.45)	(30.06)	(54.93)	131.76	(30.70)	0.64	(39.45)	(30.06)	(54.93)	131.76
	(ii) income tax relating to items that will not be reclassified to profit or loss	-	-	-	-		-	-	-	-	-		-
	b) (i) items that will be reclassified to profit or loss	-	-	-	-		-	-	-	-	-		-
	(ii) income tax relating to items that will be reclassified to profit or loss	-	-	-	-		-	-	-	-	-		-
	Total other comprehensive income/ (loss), net of income tax	**(30.70)**	**0.64**	**(39.45)**	**(30.06)**	**(54.93)**	**131.76**	**(30.70)**	**0.64**	**(39.45)**	**(30.06)**	**(54.93)**	**131.76**
14	**Total comprehensive income/ (Loss) for the period (12+13)**	**3,645.23**	**1,194.36**	**651.35**	**4,839.59**	**395.33**	**3,593.76**	**2,828.71**	**323.08**	**(129.29)**	**3,151.79**	**(713.99)**	**1,127.67**
15	Paid-up equity share capital (Including Shares pending allotment on account of Merger)	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52
	Other Equity						1,58,679.07						1,50,442.18
	Face value per share (Rs)	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
16	**Earnings per equity share *:**												
	- Basic (Rs.)	6.14	1.99	1.15	8.13	0.75	5.78	4.77	0.54	(0.15)	5.31	(1.10)	1.66
	- Diluted (Rs.)	6.14	1.99	1.15	8.13	0.75	5.78	4.77	0.54	(0.15)	5.31	(1.10)	1.66

' * EPS for the quarters are not annualised

SINGHI & CO. Chartered Accountants

ORCHID PHARMA LIMITED Gurgaon

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd...)

Statement of assets and liabilities

(in lakhs)

Particulars	Standalone		Consolidated	
	As at September 30, 2026 (Unaudited)	As at March 31, 2026 Revised (Audited) Refer Note 6	As at September 30, 2026 (Unaudited)	As at March 31, 2026 Revised (Audited) Refer Note 6
ASSETS				
Non-current assets				
Property, plant and equipment	69,659.91	66,507.07	72,220.35	68,660.78
Intangible assets	6,227.96	59.59	6,227.96	59.59
Capital work in progress	19,612.41	9,499.77	68,811.59	34,052.11
Intangible Assets under Development	1,584.71	7,307.98	2,497.65	7,307.98
Right to use assets	460.77	492.89	460.77	492.89
Financial assets				
Investments	7,334.37	8,759.22	5,490.00	6,696.59
Loans to Subsidiaries	36,264.85	18,249.10	-	-
Other financial assets	927.40	661.12	1,435.79	661.12
Non current tax assets (net)	6,044.89	5,981.96	6,044.89	5,990.61
Other non-current assets	778.65	4,100.73	6,546.98	8,994.65
Total non-current assets	**1,48,895.92**	**1,21,619.43**	**1,69,735.98**	**1,32,916.32**
Current assets				
Inventories	42,210.93	37,231.10	42,210.93	37,231.10
Financial assets				
Trade receivables	34,816.34	38,135.01	34,816.34	38,135.01
Cash and cash equivalents	2,392.59	130.46	4,661.86	707.30
Bank balances other than above	349.48	6,520.83	964.86	7,644.60
Other financial assets	186.24	106.27	142.83	129.46
Current tax assets (net)	-	-	13.37	-
Deferred tax assets (net)	-	-	26.54	29.28
Other current assets	7,839.51	6,020.17	12,662.71	9,049.70
Total current assets	**87,795.09**	**88,143.84**	**95,499.44**	**92,926.45**
TOTAL ASSETS	**2,36,691.01**	**2,09,763.27**	**2,65,235.42**	**2,25,842.77**

SINGHI & CO. Chartered Accountants

ORCHID PHARMA LIMITED Gurgaon

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd...)

Statement of assets and liabilities (Contd..) (in lakhs)

Particulars	Standalone		Consolidated	
	As at September 30, 2026 (Unaudited)	As at March 31, 2026 Revised (Audited) Refer Note 6	As at September 30, 2026 (Unaudited)	As at March 31, 2026 Revised (Audited) Refer Note 6
EQUITY AND LIABILITIES				
Equity				
Equity share capital	5,988.52	5,988.52	5,988.52	5,988.52
Other equity	1,63,313.53	1,58,679.07	1,57,239.64	1,50,442.18
Total equity	**1,69,302.05**	**1,64,667.59**	**1,63,228.16**	**1,56,430.70**
Liabilities				
Non-current liabilities				
Financial liabilities				
Borrowings	10,125.45	3,562.98	33,905.78	18,473.70
Lease liabilities	455.37	472.48	455.37	472.48
Provisions	795.51	1,344.93	795.51	1,344.93
Other non current liabilities	952.53	211.55	1,617.72	-
Total non-current liabilities	**12,328.86**	**5,591.94**	**36,774.38**	**20,291.11**
Current liabilities				
Financial liabilities				
Borrowings	17,580.47	8,790.88	20,459.76	11,670.17
Lease liabilities	36.81	38.54	36.81	38.54
Trade payables				
- Outstanding Dues of Micro and Small Enterprises	1,194.62	1,029.75	1,194.62	1,029.75
- Outstanding Dues of Creditors other than Micro and Small Enterprises	32,605.91	26,608.30	38,438.63	33,641.13
Other financial liabilities	-	134.32	-	134.33
Short term provisions	202.34	80.44	202.34	80.44
Other current liabilities	3,439.95	2,821.51	4,900.72	2,526.60
Total current liabilities	**55,060.10**	**39,503.74**	**65,232.88**	**49,120.96**
Total Liabilities	**67,388.96**	**45,095.68**	**1,02,007.26**	**69,412.07**
TOTAL EQUITY AND LIABILITIES	**2,36,691.01**	**2,09,763.27**	**2,65,235.42**	**2,25,842.77**

SINGHI & CO. Chartered Accountants

ORCHID PHARMA LIMITED Gurgaon

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd...)

Standalone and Consolidated Statement of cash flows

(in lakhs)

Particulars	Standalone		Consolidated	
	As at September 30, 2026 (Unaudited)	As at September 30, 2025 Revised (Unaudited) (Refer Note 6)	As at September 30, 2026 (Unaudited)	As at September 30, 2025 Revised (Unaudited) (Refer Note 6)
Cash Flow From Operating Activities				
Profit/ loss before income tax	4,869.65	450.26	2,948.64	(673.89)
Adjustments for				
Depreciation and amortisation expense	2,221.80	2,123.71	2,236.10	2,134.72
(Profit)/ loss on sale of fixed assets	(168.79)	(839.11)	(168.79)	(839.11)
Interest income	(1,867.90)	(1,250.07)	(169.72)	(563.02)
Unrealised forex gain/ (loss)	(527.70)	(866.30)	(527.70)	(866.30)
Bad Debts written off	3.15		3.15	
Allowance for expected credit loss	590.51	52.79	590.51	52.79
Finance costs	587.35	485.29	587.35	485.29
Share of loss or profit from Partnership firm	-	570.76	-	570.76
Loss on divestment of Investment in Partnership Firm	334.11	-	334.11	-
Share of (Profit)/loss from associates under equity method	-	-	(235.95)	118.93
Dividend Income	(0.04)	-	(0.04)	-
Provision no longer required written back	(5.51)	-	(5.51)	-
	6,036.63	727.33	5,592.15	420.17
Change in operating assets and liabilities				
(Increase)/ decrease in Other financial assets	(409.11)	(21.55)	(47.67)	(21.55)
(Increase)/ decrease in inventories	(4,979.83)	4,955.46	(4,979.83)	4,955.46
(Increase)/ decrease in trade receivables	3,316.45	3,798.38	3,316.45	3,798.23
(Increase)/ decrease in Other assets	(1,822.49)	1,770.02	(3,658.03)	1,418.10
Increase/ (decrease) in provisions and other liabilities	890.60	(994.57)	4,403.11	(912.15)
Increase/ (decrease) in trade payables	6,101.89	(10,603.11)	7,219.93	(10,436.06)
Cash generated from operations	**9,134.14**	**(368.04)**	**11,846.11**	**(777.80)**
Add : Income taxes Paid / refund received (net of payments)	(62.93)	310.62	(67.65)	307.40
Net cash from operating activities (A)	**9,071.21**	**(57.42)**	**11,778.46**	**(470.40)**
Cash Flows From Investing Activities				
Purchase of Property, plant and equipment (including changes in CWIP)	(12,800.40)	(6,679.41)	(39,543.65)	(16,390.76)

SINGHI & CO. Chartered Accountants

ORCHID PHARMA LIMITED Gurgaon

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd...)

Sale proceeds of Property, plant and equipment	391.02	896.62	391.02	896.62
(Purchase)/ disposal proceeds of Investments	883.52	(919.83)	901.21	(890.88)
(Investments in)/ Maturity of fixed deposits with banks	6,171.35	7,373.61	6,679.74	7,270.61
Loans advanced to Subsidiaries	(18,015.75)	(2,306.01)	-	-
Repayment of unsecured loan given	-	1,000.00	-	1,000.00
Dividend received	0.04	-	0.04	-
Interest received	1,930.76	1,533.23	113.42	866.11
Net cash used in investing activities (B)	**(21,439.46)**	**898.21**	**(31,458.22)**	**(7,248.30)**
Cash Flows From Financing Activities				
Proceeds from issue of equity share capital (net of share issue expenses)			-	-
Proceeds / (Repayment) of Short term Borrowings (net)	8,789.59	1,608.55	8,789.59	1,599.55
Proceeds / (Repayment) of Long term Borrowings (net)	6,562.47	219.74	15,432.08	8,665.89
Finance costs	(721.68)	(457.56)	(587.35)	(457.56)
Net cash from/ (used in) financing activities (C)	**14,630.38**	**1,370.73**	**23,634.32**	**9,807.88**
Net increase/decrease in cash and cash equivalents (A+B+C)	**2,262.13**	**2,211.52**	**3,954.56**	**2,089.18**
Cash and cash equivalents at the beginning of the financial year	130.46	1,594.17	707.30	2,117.77
Cash and cash equivalents at end of the period	**2,392.59**	**3,805.69**	**4,661.86**	**4,206.95**

SINGHI & CO. Chartered Accountants

ORCHID PHARMA LIMITED Gurgaon

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd...)

Notes:

1 The above results for the quarter and half year ended September 30, 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on November 14, 2026.The statutory auditors of the company have expressed an unmodified conclusion on the unaudited Standalone and and consolidated results.

2 The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable.

3 a)The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes', which became effective from 21st November 2025. However, the new Rules are yet to be notified even as on date.
During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company recognised a provision of Rs. 711.27 lakhs towards incremental estimated liabilities for past service cost relating to gratuity and leave, which was disclosed under "Exceptional items".
Thereafter, based on subsequent FAQ's and clarifications issued by the Ministry of Labour, deliberations at various forums and detailed examination of various provisions of the above new Labour Codes, the Company, based on Actuarial Valuation, has determined that the incremental estimated liabilities as on March 31, 2026 on account of past service cost in relation to Gratuity and Leave liability amounted to Rs.733.29 Lakhs. Hence the differential provision of Rs.22.02 Lakhs has been made in the March 2026 quarter under "Exceptional items".
The Company continues to monitor the finalisation of Central / State Rules and further clarifications from the Government on other aspects of the Labour Codes and will account for any additional impact, if required, based on such developments.

4 The Net Proceeds of Rs.39180 Lakhs raised on 27th June 2023 by way of Qualified Institutional Placement (QIP) was received by the Company and the Statement of Net funds raised and its utilisation as on September 30, 2026 is furnished below :

Statement of QIP Net Funds raised and utilisation

Particulars	Amount as stated in the Offer Document (Rs. in Lakhs) (Revised)	Total amount utilised upto Sep 30, 2026 (Rs. In Lakhs)	* Balance amount as on Sep 30, 2026 kept in Fixed deposits (Rs. In Lakhs)	Remarks
1) Investment in OBPL (subsidiary) for setting up Jammu Manufacturing Facility	13,500	13,500	-	
2) Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company	19,546	19,546	-	
3) Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu	36	36	-	
4) General corporate purposes	6,372	6,372	-	
Total	**39,454**	**39,454**	-	

#As per the QIP offer document the amount allocated for General Corporate Purpose (GCP) was ₹ 6098 Lakhs which was based on the proposed net proceeds after issue expenses being ₹ 39180 Lakhs. However, net proceeds transferred to Monitoring Account was ₹ 39,454 Lakhs as against the proposed Net Proceeds of ₹ 39,180 Lakhs, therefore the surplus amount of₹ 274 Lakhs has been included in the GCP Balance as on September 30, 2026 . The Allocation among the objects has been revised vide Shareholder's resolution dated September 20, 2025
The net proceeds from QIP has been fully utilitised as on September 30, 2026

5 The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable.

6 Pursuant to the Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited ("Transferor Company") and Orchid Pharma Limited ("Company" or "Transferee Company") and their respective shareholders and creditors ("Scheme"), sanctioned by the Hon'ble National Company Law Tribunal, Chennai Bench ("NCLT") vide its order dated June 05, 2026, the Transferor Company has been amalgamated with and into the Company. The Scheme has an appointed date of April 01, 2024 and became effective on July 10, 2026 upon filing of the certified copy of the NCLT order with the Registrar of Companies, Chennai. In accordance with the terms of the Scheme and the applicable provisions of Ind AS, the amalgamation has been accounted for from the appointed date. Accordingly, the financial results for the quarter and half year ended September 30, 2026 and the comparative periods presented therein have been prepared/restated, respectively, to give effect to the amalgamation from the appointed date, as applicable.

During the quarter ended September 30, 2026, the business of Synmedic Laboratories, a partnership firm, stood transferred to the Company on a going concern basis through a slump sale pursuant to the Business Transfer Agreement (BTA), which was consummated by Dhanuka Laboratories Limited (DLL) (since amalgamated into the Company) and became effective on July 3, 2026. Accordingly, the business, along with the related assets and liabilities, has been accounted for in the financial statements in accordance with the applicable accounting principles.

7 Figures of the previous period have been regroupted/reclassified /restated wherever considered necessary

For and on behalf of the Board

Manish Dhanuka
Managing Director
Din: 00238798

ORCHID PHARMA LIMITED Gurgaon

Place: Gurugram
Date : November 14, 2026

Initiated for identification purposes

SINGHI & CO. Chartered Accountants

Singhi & Co.
Chartered Accountants
Unit 11-D, 11th Floor, Ega Trade Centre, 809, Poonamallee High Road, Kilpauk, Chennai-600 010 India
Ph: +91 44 42918459, E-mail :chennai@singhico.com Website : www.singhico.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Orchid Pharma Limited** ("the Company") for the quarter and half year ended September 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards ('IND AS') prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For Singhi & Co.
Chartered Accountants
Firm Regn. No. 302049E

SINGHI & CO Chartered Accountants

Sudesh Choraria
Partner
Membership No.204936
UDIN: 26204936FCCMGG7130

Place: Mumbai
Date: November 14, 2026

Singhi & Co.
Chartered Accountants
Unit 11-D, 11th Floor, Ega Trade Centre, 809, Poonamallee High Road, Kilpauk, Chennai-600 010 India
Ph: +91 44 42918459, E-mail :chennai@singhico.com Website : www.singhico.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Orchid Pharma Limited** (hereinafter referred to as "the Parent Company") and its subsidiaries (the Parent Company and its Subsidiaries together referred to as " the Group") and its associate for the quarter and half year ended September 30,2026 ("the Statement") attached herewith being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent Company's Management and has been approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to issue a conclusion on these financial results based on the review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
   i) Orchid Pharmaceuticals Inc., USA
   ii) Bexel Pharmaceuticals Inc., USA
   iii) Diakron Pharmaceuticals, Inc. USA
   iv) Orchid Bio-Pharma Limited
   v) Orchid Pharma Europe GmbH (w.e.f. 30th July 2025)

   The unaudited consolidated financial results also include the results of M/s Orbion Pharmaceuticals Private Limited, an associate company accounted under equity method.



We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

5. **Other matters**:

a) We did not review the financial information of 1 subsidiary included in the statement, whose financial information reflects total assets of Rs. 67,391.05 lakhs as at September 30 2026, revenue from operations of Rs.Nil and Rs.Nil, net profit after tax of Rs. 27.55 lakhs and Rs. 8.14 lakhs, total comprehensive income after tax of Rs. 27.55 lakhs and Rs. 8.14 lakhs for the quarter and half year ended September 30, 2026 respectively and net cash inflow Rs.1210.91 lakhs for the half year ended September 30, 2026 as considered in this statement. These financial information have been reviewed by other auditors whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matter.

b) We did not review the interim financial results of 4 subsidiaries whose financial information reflects total assets (before consolidation adjustments) of Rs.1855.18 lakhs as at September 30 2026, revenue from operations of Rs.Nil and Rs.Nil, net profit after tax of Rs160.95 lakhs and Rs (0.24) lakhs, total comprehensive income after tax of Rs160.95 lakhs and Rs (0.24) lakhs for the quarter and half year ended September 30, 2026 respectively and net cash inflow of Rs.481.51 Lakhs for the half year ended September 30, 2026 as considered in the unaudited consolidated financial results.

We also did not review the Group's share of net Profit / (loss) (after tax) of Rs.171.23 Lakhs and Rs.235.95 Lakhs of the associate for the quarter and half year ended September 30, 2026, as considered in the unaudited consolidated financial results.

The financial information of the above subsidiaries and associate are unaudited and have been furnished to us by the management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and associate, is based solely on such unaudited financial results.

Our Conclusion is not modified in respect of the above matters.


6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other



accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co.,
Chartered Accountants
Firm Regn. No. 302049E





Sudesh Choraria
Partner
Membership No.204936
UDIN: 26204936TVLGCN6657

Place: Mumbai
Date: November 14, 2026